Abstract
Recently, rhIL-11 was developed as an enteric-coated In Vivo Absorption Properties of multiparticulate formulation for oral dosing of patients with Orally Administered Recombinant inflammatory bowel disease. Therefore, we conducted a series of PK studies to examine the systemic bioavailability and bioHuman Interleukin-11 distribution of orally administered rhIL-11 to support its proposed clinical use.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
